Active Investments

Akari Therapeutics

Private

Audentes Therapeutics

Private

AveXis

Private

KalVista Pharmaceuticals

Private

REGENXBIO

Public (NASDAQ: RGNX)

Replicor

Private

Avalanche Biotech

Public (NASDAQ: AAVL)

DBV Technologies

Public (NYSE: DBV)

Ocera Therapeutics

Public (NASDAQ: OCRX)

Alumni Investments

Juno Therapeutics

Public (NASDAQ: JUNO)

Ardea Biosciences

Acquired by AstraZeneca

Dyax

Public (NASDAQ: DYAX)

Medivation

Public (NASDAQ: MDVN)

Neurocrine Biosciences

Public (NASDAQ: NBIX)

NPS Pharmaceuticals

Public (NASDAQ: NPSP)

YM Biosciences

Acquired by Gilead

Bong Koh Partner

Focus Areas: Biotechnology
Location: New York

Bong originally joined Venrock in 2009 and has been doing public and private investing since 2004. He did his medical training at Harvard’s Mass Eye & Ear Infirmary (ophthalmology), Stanford Hospital (internal medicine) and UCSF (pathology).

Bong is a manager of Venrock’s public and cross-over biotech fund, Venrock Healthcare Capital Partners, where he provides leadership in biotech investments. Bong is on the AveXis’ board of directors.

Bong earned his B.A. from Yale University, his M.D. from the University of California, San Francisco, and an M.B.A. from Harvard Business School.

Active Companies

Akari Therapeutics

Audentes Therapeutics

AveXis

KalVista Pharmaceuticals

REGENXBIO

Replicor

Avalanche Biotech

DBV Technologies

Ocera Therapeutics

Alumni Companies

Juno Therapeutics

Ardea Biosciences

Dyax

Medivation

Neurocrine Biosciences

NPS Pharmaceuticals

YM Biosciences